News

Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and ...
InvestorsHub on MSN1d
Rani Therapeutics Shares Surge After ENDO 2025 Presentation Announcement
Rani Therapeutics Holdings Inc (NASDAQ:RANI) experienced an 18% jump in its stock price following news that the ...
Science Daily5h
Obesity is driving a hidden cancer epidemic—13 types and rising deaths nationwide
Obesity-related cancer deaths in the U.S. have tripled in just two decades, with women, older adults, and minority groups ...
Aspect Biosystems Presents New Preclinical Data on Adrenal Bioprinted Tissue Therapeutics at ENDO 2025
Aspect Biosystems presents preclinical data showing potential of its adrenal BTTs to restore adrenal function and treat ...
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
Data show that PALSONIFY was well tolerated and IGF-1 levels remained stably controlled during long-term open label ...
The Bakersfield Californian1d
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating ...
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics ...
Endocrinology Advisor3d
ENDO 2025: Advances in PCOS, Obesity, Diabetes, and Endocrine Disorder Research
ENDO 2025 spotlights breakthrough research in PCOS, obesity, diabetes, and rare endocrine disorders and offers practical updates for daily clinical care. As the sun rises over San Francisco, ...